News

Intellia Therapeutics (NASDAQ:NTLA), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was

Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt

Imagine being able to buy a machine that would work day after day and year after year to make you money. Now imagine being able to buy several such machines. This would be a utopia for anyone

Image source: The Motley Fool.

MannKind (NASDAQ: MNKD)Q4 2024 Earnings CallFeb 26, 2025, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Sarepta Therapeutics (NASDAQ: SRPT)Q4 2024 Earnings CallFeb 26, 2025, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m. ET and had been down as much as 38.7% earlier in the session.

Geron

Image source: The Motley Fool.

Geron (NASDAQ: GERN)Q4 2024 Earnings CallFeb 26, 2025, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

When it comes to artificial intelligence (AI) chip stocks, my guess is that names such as Nvidia, Broadcom, or Advanced Micro Devices come to mind first. While all three companies are playing an

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss

Masimo (NASDAQ:MASI), a provider of noninvasive patient monitoring technology, released its fourth-quarter earnings for 2024, on Feb. 25, 2025. The results presented a mixed picture: strong

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases.

In one, Lilly announced plans to acquire the farnesoid X

One of the cornerstones of President Donald Trump's campaign was a promise to bring more manufacturing jobs back to the U.S. from overseas. In particular, the new administration has been focused on

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the

A higher dividend yield is nice because it allows you to collect more dividend income on every dollar you invest in a stock. However, the company paying that dividend needs to be healthy to ensure

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion

With its shares more than doubling year to date, Super Micro Computer (NASDAQ: SMCI) is bouncing back from the crisis caused by uncertainty about its accounting practices. But is this recovery a

Buying quality stocks when they're unpopular can be very rewarding.

A good place to look for unpopular stocks these days is in the healthcare sector, as Robert F. Kennedy Jr.'s nomination and

It is a beautiful thing when you find a feel-good stock that offers market-beating potential. A perfect example of this combination today is animal healthcare specialist Zoetis (NYSE: ZTS).

Whether

The U.S. stock market, characterized by the S&P 500, has been on a tear since the artificial intelligence (AI) revolution began in early 2023. The index has risen approximately 24% over the past